Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03315975 · ClinicalTrials.gov registry record · Phase 4
Flu Vaccine Responses in the Setting of Melanoma Treatment
A Phase 4 study of Viral Vaccines, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT03315975 is a Phase 4 study of Viral Vaccines that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03315975, a Phase 4 study of Viral Vaccines, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Influenza vaccination is indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. We are conducting a prospective unblinded study of influenza vaccine recipients.
Conditions Studied
Interventions
- BIOLOGICAL Inactivated influenza vaccine
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03315975
The ClinicalTrials.gov registry entry for NCT03315975 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Viral Vaccines appearing as the primary indexed condition, and to 1 intervention - of which Inactivated influenza vaccine is the first listed.
NCT03315975 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03315975 about?
NCT03315975 is a clinical study titled "Flu Vaccine Responses in the Setting of Melanoma Treatment". Influenza vaccination is indicated for all adults, but the immunogenicity of vaccination has not been assessed in all situations. We are conducting a prospective unblinded study of influenza vaccine recipients.
What is the current status of trial NCT03315975?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2017-10-20. Estimated completion is 2026-07-01.
What conditions does trial NCT03315975 study?
This clinical trial studies the following conditions: Viral Vaccines.
What interventions are being tested in trial NCT03315975?
The interventions under investigation include: Inactivated influenza vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT03315975?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03315975 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Vaccines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.